Factor XI Inhibitors: A New Horizon in Anticoagulation Therapy
Authors:
Open Access
- 2 February 2024
- journal article
- review article
- Published by Springer Nature in Cardiology and Therapy
- Vol. 13 (1) , 1-16
Abstract
Anticoagulation therapy has undergone significant evolution, marked by the emergence of direct oral anticoagulants with distinct advantages. Despite these advancements, challenges persist in managing residual thrombotic and bleeding risks, particularly among vulnerable populations. The pursuit of alternative drugs has honed in on factor XI/XIa inhibitors. This comprehensive review delves into several key aspects regarding this new target: (i) the role of factor XI in the coagulation cascade; (ii) the genetic evidence and pathophysiologic rationale supporting factor XI inhibition as a therapeutic target; (iii) an exploration of the various types of factor XI/XIa inhibitors currently under investigation; (iv) potential applications of these medications, spanning thromboprophylaxis after orthopedic surgery, stroke prevention in atrial fibrillation, secondary prevention after acute coronary syndrome, non-cardioembolic stroke, thromboprophylaxis after foreign material implantation, end-stage renal disease, and patients with cancer; and (v) an overview of ongoing studies, recent findings, and the future trajectory of research into these drugs.Keywords
This publication has 49 references indexed in Scilit:
- Edoxaban versus Warfarin in Patients with Atrial FibrillationNew England Journal of Medicine, 2013
- Dabigatran versus Warfarin in Patients with Mechanical Heart ValvesNew England Journal of Medicine, 2013
- Rivaroxaban in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- Rivaroxaban versus Warfarin in Nonvalvular Atrial FibrillationNew England Journal of Medicine, 2011
- Factor XI deficiency in humansJournal of Thrombosis and Haemostasis, 2009
- Reduced incidence of ischemic stroke in patients with severe factor XI deficiencyBlood, 2008
- Factor XI–dependence of surface- and tissue factor–initiated thrombus propagation in primatesBlood, 2003
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture SurgeryNew England Journal of Medicine, 2001
- Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Elective Major Knee SurgeryNew England Journal of Medicine, 2001
- Factor XI Activation in a Revised Model of Blood CoagulationScience, 1991